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ABSTRACT
Introduction: Chronic pelvic pain (CPP) affects >1
million UK women. Annual healthcare costs are
estimated at >£150 million. Proven interventions for
CPP are limited, and treatment is often unsatisfactory.
Gabapentin is increasingly prescribed due to reports of
effectiveness in other chronic pain conditions, but
there are insufficient data supporting value in CPP
specifically. The mechanism by which gabapentin
exerts its analgesic action is unknown. Given the
prevalence and costs of CPP, the authors believe that
a large, multicentre, placebo-controlled, double-blind
randomised controlled trial to evaluate the efficacy of
gabapentin in management of CPP is required. The
focus of this study is a pilot to inform planning of
a future randomised controlled trial.
Methods and analysis: The authors plan to perform
a two-arm, parallel, randomised controlled pilot trial.
The authors aim to recruit 60 women with CPP in NHS
Lothian and NHS Grampian (UK) and randomise them
to gabapentin or placebo. Response to treatment will be
monitored by questionnaire compared at 0, 3 and
6 months. The primary objective is to assess
recruitment and retention rates. The secondary
objectives are to determine the effectiveness and
acceptability to participants of the proposed methods of
recruitment, randomisation, drug treatments and
assessment tools and to perform a pretrial cost-
effectiveness assessment of treatment with gabapentin.
Ethics and dissemination: Ethical approval has been
obtained from the Scotland A Research Ethics
Committee (LREC 12/SS/0005). Data will be presented
at international conferences and published in peer-
reviewed journals.
Trial registration number: ISRCTN70960777.
INTRODUCTION
Chronic pelvic pain (CPP) affects over 1
million women in the UK.1 2 It is the reason
for 20% of gynaecological consultations and
causes a 45% reduction in work productivity.3
The annual cost for caring for UK women
with CPP has been estimated at £154 million.
The cause of the painful symptoms experi-
enced by women with CPP is poorly under-
stood. Pain is often associated with specific
pathological processes, such as endometri-
osis, but up to 55% of women with CPP
appear to have no obvious underlying
pathology.2 The management of CPP is
difficult4 because in the absence of under-
lying pathology, no established gynaeco-
logical treatments are available.
Gabapentin (a GABA analogue) is being
increasingly prescribed in general practice
for CPP. It is also recommended by some
practitioners as a treatment of choice for CPP
in a multidisciplinary setting, despite no
clinical evidence on which to base this
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ARTICLE SUMMARY
Article focus
- Is it possible to achieve acceptable recruitment
and retention rates in a two-arm, parallel,
randomised controlled pilot trial of women with
CPP given gabapentin and placebo?
- Are the proposed methods of recruitment,
randomisation, drug treatments and assessment
tools in this pilot trial effective and acceptable to
participants?
- Is gabapentin likely to be cost effective for the
management of CPP in women given the current
level of uncertainty?
Key messages
- CPP affects >1 million UK women, and treat-
ments are often unsatisfactory.
- Gabapentin is being increasingly prescribed due
to reports of effectiveness in other chronic pain
conditions, but there are insufficient data
supporting its value in CPP specifically.
- A large, multicentre, placebo-controlled, double-
blind randomised controlled trial (RCT) to
evaluate the efficacy of gabapentin in manage-
ment of CPP is required.
- The focus of this study is a pilot to inform
planning of a future RCT.
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recommendation. To our knowledge, only one study has
evaluated the use of gabapentin for CPP. This small study
(56 patients) compared gabapentin against amitriptyline
for treatment of CPP and showed that gabapentin had
greater efficacy (80% compared with 70% improvement
in pain scores at 12 months).5 Unfortunately, this study
had no placebo arm and the significance of the effect on
quality of life provided by gabapentin in the manage-
ment of CPP was not evaluated. Nevertheless, the efficacy
of gabapentin has been documented for other chronic
pain conditions: painful diabetic neuropathy, post-
herpetic neuralgia, mixed neuropathic pain conditions,
spinal cord injury and phantom limb pain.6 The number
needed to treat for improvement in all trials with
evaluable data is 4.3 (95% CI 3.5 to 5.7). In some of
these trials, gabapentin also improved sleep, mood and
other elements of quality of life. The mechanism by
which gabapentin exerts its analgesic action is unknown.
Ideally, a definitive evaluation of the efficacy of gaba-
pentin in the management of CPP with no obvious
underlying pathology requires a large, multicentre
randomised controlled trial (RCT). This protocol
outlines a pilot study to assess the processes that are vital
to the delivery of such a trial.
Objectives
Primary objective
The primary objective is to determine whether it is
possible to achieve acceptable recruitment and retention
rates in two UK centres (NHS Lothian and NHS Gram-
pian) within defined inclusion/exclusion criteria.
Secondary objectives
1. To determine the effectiveness and acceptability to
patients of the proposed methods of recruitment,
randomisation, drug treatments and assessment tools.
2. To determine whether gabapentin is likely to be cost
effective given the current level of uncertainty and to
ascertain what further evidence is needed for the
evaluation of gabapentin.
End points
Primary end points
1. The proportion of eligible patients randomised into
the study.
2. The proportion of randomised patients who take all
their medication and fully complete questionnaires at
final follow-up.
Secondary end points
Data on effectiveness and acceptability of proposed
methods of recruitment, randomisation, drug treat-
ments and assessment tools will be used to refine
the design of the definitive RCT. The potential cost-
effectiveness of gabapentin in the management of CPP
will also be determined.
METHODS AND ANALYSIS
Study design
We aim to perform a two-arm, parallel, randomised
controlled pilot trial (figure 1). This will be a two-centre
study with recruiting in NHS Lothian (Edinburgh) and
NHS Grampian (Aberdeen). We will recruit 60 patients
over approximately 9 months. After randomisation, the
participants will receive treatment for 6 months. Partici-
pants and the healthcare team will be unblinded at the
end of their treatment.
Subjects
A total of 60 women aged 18e50 years with a history of
pelvic pain (cyclical or non-cyclical) and/or dyspareunia
with no obvious pelvic pathology detected at laparoscopy
will be invited to participate in the trial.
Study settings
We will recruit patients from gynaecology outpatient
clinics, gynaecology wards and day surgery units within
NHS Lothian and NHS Grampian.
Sample size
We have used a CI approach7 to estimate the sample size
to establish feasibility based on a loss to follow-up of
<20%. A 95% CI for 20% of 60 patients (12/60) is 11%e
32%. We estimate that we will recruit approximately
three to four patients per month from each centre and
aim to recruit 60 patients over a 9-month recruitment
period. Each centre performs six to seven laparoscopies
per month that fit the inclusion criteria.
Inclusion criteria
< Women aged between 18 and 50 years.
< Pelvic pain of >6 months.
< Pain located within the true pelvis or between andbelow
anterior iliac crests, associated functional disability.
< No obvious pelvic pathology at laparoscopy (<6
months and >2 weeks ago).
< Using effective contraception.
ARTICLE SUMMARY
Strengths and limitations of this study
- We recognise that there may be potential difficulties in
mounting a large RCT for a chronic pain condition using
gabapentin (a medication with known sedating side effects).
- We have designed this pilot study to assess practical feasibility.
- The study has been designed following the ‘Initiative on
Methods, Measurement, and Pain Assessment in Clinical Trials’
recommendations for the design of chronic pain clinical trials.
- Gabapentin requires titration to achieve an efficacious dose so
that the rate and severity of adverse effects are minimised.
- We have included focus group assessment of the acceptability
of the drug treatment and titrating regime in our study to
inform the design of the future RCT.
- We plan to use a wide range of data collection tools in our
study, but it is our intention to use fewer in our future RCT
depending on their effectiveness in the pilot study (defined by
lack of missing data, ability to detect effect and independence)
and participant feedback on acceptability.
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Exclusion criteria
< Known pelvic pathology, for example, endometriosis,
cyst.
< Taking gabapentin or pregabalin.
< Due to undergo surgery in the next 6 months.
< History of significant renal impairment.
< Allergic to gabapentin.
< Breast feeding.
< Pregnancy or planning pregnancy in the next
6 months.
Participant enrolment
All gynaecology consultants within NHS Lothian and
NHS Grampian will be sent a letter informing them of
the study and requesting permission to approach their
patients. Two research nurses (one in NHS Lothian and
one in NHS Grampian) will be employed for the dura-
tion of the study to approach eligible women, provide
them with patient information sheets and offer them the
opportunity to discuss the trial, and obtain informed
consent. Consent will only be taken once the patient has
had ample time to read the patient information sheet
and had her questions answered.
Intervention and randomisation
Eligible women will be randomised to either gabapentin
or placebo using a web-based system. Women will be
stratified by centre (NHS Lothian and NHS Grampian).
We will use randomised blocks of varying sizes.
Dose regime
Participants will start on 300 mg gabapentin daily and
will increase in 300 mg increments each week until they
report a 50% pain reduction or side effects (eg,
Figure 1 Flow of participants
through the study. QoL, quality of
life.
Women with chronic pelvic pain in whom diagnostic
laparoscopy reveals no pelvic pathology
n=100–170 
60 women with chronic pelvic pain randomised
at laparoscopy to treatment with gabapentin
or placebo for 6 months
Treatment diaries
All participants
Visual Analogue Scale (VAS)
Brief Pain Inventory (BPI)
Pain Disability Questionnaire (PDQ)
Hospital and Anxiety Depression Score (HADS)
QoL Questionnaire (EQ5D)
WHO QoL Questionnaire
MYMOP Questionnaire
0, 3 and 6 months
Primary: determine recruitment and retention rates.
Other: effectiveness and acceptability of interventions and 
data collection tools, change in VAS, BPI, PDQ, HADS, 
EQ5D, WHO QoL and MYMOP scores, cost-effectiveness 
of gabapentin. 
Research outcomes
Gabapentin
n=30
Placebo
n=30
Number of
ineligible patients
Data Collection
Reasons
patients not enrolled
Reasons for
withdrawal
Pretrial economic
model and value of
information analysis
Those with endometriosis
and other exclusion
criteria excluded
Focus group discussions
Purposive sample
n=20–24
Anonymous questionnaires
All participants
Dose escalated or
reduced as per protocol
Adverse events
Acceptability of
interventions
Information on blinding
and compliance
Horne AW, Critchley HOD, Doust A, et al. BMJ Open 2012;2:e001297. doi:10.1136/bmjopen-2012-001297 3
Efficacy of gabapentin for chronic pelvic pain in women: study protocol
dizziness, somnolence, mood changes, appetite and
poor concentration), up to a maximum dose of 2700 mg.
Patients will be advised regarding their dosing regime
weekly by a member of the research team who will phone
until optimum dose is reached. It will be recommended
that the drug should be taken in three equally divided
doses daily. Participants will be advised to remain on the
maximum tolerated dose for up to 6 months. The same
protocol will be used for the placebo. When the partic-
ipant stops treatment then the dose will be tapered down
over 7e10 days at the clinician’s discretion. Patients will
be allowed to use other medication (including analge-
sics, self-medication and alternative treatments, eg,
acupuncture) throughout the study period.
Data collection
Data storage
A log with the patients’ name and date of birth will be
kept along with their unique study number in a separate
file. All the data generated from the study will be stored
in an anonymised form in a bespoke database, which will
also be password protected. Only anonymised informa-
tion will be stored on this, and participants will only be
identifiable by their study number. All paperwork will be
kept in a locked filing cabinet in a locked office. All data
will be stored on university server on a password-
protected computer with limited access to the research
team, in accordance with NHS and University of Edin-
burgh guidelines and in accordance with the Data
Protection Act.
Screening
A member of the research team will carry out a screening
visit to assess eligibility. All data will be recorded on
a case record form and transferred to a secure database.
Participant log
The clinical research team will keep an electronic log of
women who fulfil the eligibility criteria, women who are
invited to participate in the study, women recruited and
women who leave the trial early. Reasons for non-
recruitment (eg, non-eligibility, refusal to participate,
administrative error) will also be recorded. We will
attempt to collect reasons for non-participation from
women who decline to take part after previously
providing contact details. During the course of the study,
we will document reasons for withdrawal from the study
and loss to follow-up. Participants will be reviewed by the
clinical research team at 6 weeks, 3 months and
6 months.
Treatment diaries
All medications and healthcare resource use taken after
screening and any medication other than the trial
treatment taken during the study will be recorded in
a treatment diary. This includes prescription and non-
prescription treatment, such as contraceptives, vitamins,
topical preparations, herbal preparations and non-
pharmacological therapies.
Questionnaires
A questionnaire will be given to all participants at
randomisation (0 months) and at 3 months. This will
include the following validated tools:
1. Visual Analogue Scale (VAS).
2. Brief Pain Inventory.
3. Pain Disability Questionnaire.
4. Hospital Anxiety and Depression Score.
5. EQ5D QoL.
6. WHO QoL.
7. MYMOP patient-generated outcome questionnaire.
The questionnaire at 0 months will include questions
to capture the baseline demographic and clinical char-
acteristics of the participants.
A further questionnaire will also be given to all
participants at 6 months, which will include the above
and additional questions on whether they believed that
they were receiving gabapentin or placebo and also
questions on acceptability of the allocated medication/
treatment regimes (and compliance) and on the
acceptability of the above data collection methods.
Lastly, we will ask the participants to complete a brief
anonymous questionnaire once they have submitted
their treatment diaries to assess level of adherence to
diary keeping.
Focus groups
A purposive sample (based on age, social class and
severity of symptoms) of 10 Edinburgh women
(including some undergoing fMRI) and 10 Aberdeen
women will be invited to participate in focus group
discussions of the trial experience 6 months into the
trial.8 Women who do not wish to participate in a focus
group will be offered individual interviews using the
same interview schedule. This will enable important
issues arising in the focus groups to be explored in
greater depth. Up to 20 interviews will be performed.
Group/individual interviews will be audio-recorded,
transcribed verbatim and analysed thematically to iden-
tify the issues of importance to participants not covered
in the questionnaires, their feelings about trial partici-
pation and experiences with prescribed medication.
Healthcare resource utilisation measures
Information will be derived from treatment diaries and
from research nurse reviews of the participants’ hospital
and general practitioners’ records.
Adverse events
Participants will collect information about adverse events
in their treatment diaries. However, they will be
instructed to contact the clinical research team at any
time after consenting to join the trial if they have an
event that requires hospitalisation or an event that
results in persistent or significant disability or incapacity.
Gabapentin is generally well tolerated in the manage-
ment of other chronic pain conditions, and serious
adverse events are not anticipated. Any serious adverse
events that occur after joining the trial will be reported
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in detail in the participant’s medical notes, followed up
until resolution of the event and reported to the
ACCORD Research Governance (http://www.accord.ed.
ac.uk) and QA Office based at the University of Edin-
burgh immediately or within 24 h.
Termination of study
Participants (and their gynaecologists) will be
unblinded at the end of the study period (6 months).
There will be no central unblinding facility, but the site
pharmacies will be provided with the key that links drug
pack number to treatment. Thus, it will be possible
for unblinding (emergency or otherwise) to be
carried out by a pharmacist if requested. All participants
will be given the right to be unblinded, discontinue the
drug or completely withdraw from the study at any time
for any reason. Reasons for unblinding, before the
termination of the study, will be collected. Those
participants who feel that they have benefited from
treatment with gabapentin, during the study period, will
be advised to discuss continuation of treatment with
their gynaecologist.
Proposed analyses
Determine recruitment and retention rates
Using the information collected from the participant
log, we will determine the number of patients recruited
from the pool of eligible women and a >50% recruit-
ment will be deemed acceptable. While a retention rate
of 100% would be ideal, we will consider a rate of 90%
satisfactory. We will provide an estimate of the propor-
tion and its 95% CI. If retention rates are low, we will use
the information collected from the focus group discus-
sions to ascertain why and improve compliance in the
future trial. In addition, we will determine the nature
and number of unanswered questions in each ques-
tionnaire and identify reasons for non-response through
the focus groups and participant interviews in order to
optimise data collection in the future trial.
Effectiveness and acceptability of proposed methods of
recruitment, randomisation, drug treatments and assessment
tools
These areas will be explored in the focus group discus-
sions and assessed quantitatively using additional ques-
tions included in participant questionnaires
administered at 6 months. Due to the conflicting litera-
ture about the benefits of methods such as prescription
monitoring, pill counting and devices for monitoring
the self-administration of medicines,9 data on blinding
and compliance to treatment will be derived from
questionnaires at 6 months. We aim to determine if
treatment is acceptable in terms of self-reported
compliance (from treatment diaries). Although this is
a pilot study and the sample size is small, we will assess
the effect of any non-compliance on the LICKERT score
by performing protocol and intention-to-treat analyses.
This information along with health professionals’ and
clinical research nurses’ views (as assessed by question-
naire) will be used to inform the design of the future
RCT. In addition, the difference in VAS scores between
participants on gabapentin and placebo at 0 and
6 months will be assessed using analysis of covariance
adjusting for baseline VAS score.
Pretrial economic model and value of information analysis
In addition to data relating to the clinical and quality-
of-life parameters, data on healthcare resource use will
also be collected. A decision model will be developed,
from the perspective of the NHS, to estimate the costs
and health outcomes in terms of quality of life and
quality-adjusted life-years associated with gabapentin and
placebo based on the data from this pilot study and the
literature. A probabilistic decision model will be
constructed to simulate the clinical pathways associated
with gabapentin and placebo, according to the guidance
set out by National Institute for Health and Clinical
Excellence.10 The basic model structure will consist of
two arms, replicating the clinical consequences of
patients receiving gabapentin and placebo. The main
data source relating to the key parameters of the model
will be provided by the pilot study. The mean costs and
quality-adjusted life-years associated with both arms will
be calculated for the modelling period (duration of the
trial). Costeutility analysis will be carried out, and incre-
mental cost per quality-adjusted life-years gained will be
calculated. Particular consideration will be given to the
potential for cost-effectiveness to vary by particular
patient characteristics or risk groups where suggested by
the literature. Probabilistic sensitivity analysis will be used
to characterise uncertainty in parameters of the model
and presented using cost-effectiveness acceptability
curves. Standard univariate sensitivity analysis will be
carried out to explore areas of structural uncertainty in
the analysis. Finally, a value of information analysis on the
expected value of perfect information will also be carried
out to quantify potential value of further research based
on the difference between expected net benefit with
perfect information and existing information.
ETHICS AND DISSEMINATION
Ethical approval has been obtained from the Scotland A
Research Ethics Committee (LREC 12/SS/0005). Data
will be presented at international conferences and
published in peer-reviewed journals. We will make the
information obtained from the study available to the
public through national bodies and charities.
DISCUSSION
We believe that a definitive evaluation of the efficacy of
gabapentin in the management of CPP requires a multi-
centre randomised placebo-controlled trial (RCT).
Recognising that there may be potential difficulties in
mounting a large RCT for a chronic pain condition
using a medication with known sedating side effects and
that requires a titrated dosing regime, we have designed
this pilot study to assess practical feasibility following the
IMMPACT (Initiative on Methods, Measurement, and
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Pain Assessment in Clinical Trials) recommendations for
the design of chronic pain clinical trials.11 We are aware
that our pilot study has a number of positive and nega-
tive aspects, and these are discussed below.
For our pilot study, we are using the most common
design in confirmatory trials of chronic pain treatments:
a ‘parallel groups’ design.11 We will randomise partici-
pants to either gabapentin or placebo and then evaluate
recruitment and retention rates as our primary outcome.
We appreciate that this design may be limited by the fact
that the severity of the participants’ pain may preclude
them from remaining on the placebo for the 6-month
follow-up period. Therefore, the outcome of the pilot
will determine whether we need to consider alternative
designs, such as ‘crossover’, ‘randomised withdrawal’
and ‘doseeresponse’ designs, for the future RCT
assessing efficacy of gabapentin for CPP.
The criteria for inclusion and exclusion of study subjects
into our pilot study are broad in attempt to reflect the real
clinical scenario for prescribing gabapentin. The criteria
do not take into account pain intensity, do not exclude
women with non-reproductive comorbidities (eg, irritable
bowel syndrome, interstitial cystitis) that could explain
their symptoms and allow participants the use of
concomitant medications. We are aware that these char-
acteristics may increase variability in patient responsive-
ness to treatment and carry the risk of failing to
demonstrate treatment effect. We will therefore capture
this information in our pilot study in the participants’
questionnaires and treatment diaries to inform interpre-
tation of our results and the planning of the future RCT.
Like many of the medications used for chronic pain,
gabapentin requires titration to achieve an efficacious
dose so that the rate and severity of adverse effects are
minimised. The duration of this titration period may be
as many as 8e10 weeks. The 6-month follow-up in our
pilot study allows for a 12-week maintenance phase that
has become standard for confirmatory trials. It could be
argued that a longer trial would be better to assess the
long-term effects of gabapentin. On the other hand, we
are aware that extended duration could be problematic
because of the number of dropouts from the placebo
arm due to inadequate pain relief. We believe that focus
group assessment of the acceptability of the drug treat-
ment and titrating regime in our pilot will therefore be
essential in designing the future RCT.
The comparison of an investigational treatment with
placebo is considered the gold standard for assessing
efficacy and safety when a delay in the onset of treatment
does not cause any lasting adverse effects and assuming
that subjects fully understand their right to withdraw from
the trial at any time for any reason.12 13 However, gaba-
pentin is sedating and it can be argued that this increases
the likelihood that both subjects and investigators can
successfully guess to which group a subject has been
allocated. We are therefore going to ask the subjects and
investigators at the conclusion of the trial to guess the
subjects’ treatment group and the primary reason for the
guess to determine whether significant ‘unblinding’ was
present within the trial. This will determine whether we
need to use an ‘active placebo’ mimicking the side effects
of gabapentin in the future RCT.
Our data collection tools were chosen with advice from
a clinical psychologist with a specialist interest in chronic
pain and a general practitioner with a research interest
in medically unexplained symptoms. The selection of
these tools was also again based on the IMMPACT
recommendations,11 that is, the need to assess the core
domains of pain, physical/emotional functioning
(including sleeping difficulties), improvement/satisfac-
tion with treatment, symptoms and adverse events and
participant disposition. We plan to use a wide range of
data collection tools, but it is our intention to use fewer
in our future RCT depending on their effectiveness in
the pilot study (defined by lack of missing data, ability to
detect effect and independence) and participant feed-
back on acceptability.
We also aim to determine whether gabapentin is
expected to be cost effective given the current level of
evidence and uncertainty through an iterative approach
to economic evaluation of health technologies.14 15
Important gaps and uncertainty surrounding existing
data and the expected cost-effectiveness will be explored
through synthesis, modelling and value of information
analysis prior to a definitive RCT. We will determine
whether further evidence is needed to reduce the
uncertainty surrounding cost-effectiveness, and if so,
identify the focus of further research in terms of study
design and data collection; this may have implications on
determining an appropriate sample size (eg, powered to
detect difference in clinical effect or cost-effectiveness).
Finally, although the primary outcome in our pilot
study is to determine recruitment and retention rates, we
will also measure change in VAS over 6 months. This
combination of information will allow us to determine
the effect size and SD and plan the sample size for the
definitive RCT. Analyses of similar studies using gaba-
pentin for chronic pain with VAS score as primary
outcome indicate that the mean absolute difference in
the VAS score comparing gabapentin against placebo
ranges between 0.8 and 1.8, with an SD of approximately
2.5 after 1e2 months of treatment.6 Thus, our definitive
RCT is likely to be powered to find a difference of >1.2
on the VAS scale (a clinically important symptom alle-
viation is defined as a reduction in VAS of >1.216
between the gabapentin and placebo arms of the study.)
Author affiliations
1MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh, UK
2Universita¨res Interdisziplina¨res Kinderwunschzentrum Du¨sseldorf,
Du¨sseldorf, Germany
3Department of Anaesthesia, Royal Infirmary of Edinburgh, Edinburgh, UK
4Health Economics and Health Technology Assessment, Institute of Health and
Wellbeing, University of Glasgow, Glasgow, UK
5Department of Gynaecology, Aberdeen Royal Infirmary, Aberdeen, UK
6Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK
7Centre for Population Health Sciences, University of Edinburgh, Edinburgh,
UK
6 Horne AW, Critchley HOD, Doust A, et al. BMJ Open 2012;2:e001297. doi:10.1136/bmjopen-2012-001297
Efficacy of gabapentin for chronic pelvic pain in women: study protocol
Contributors AH: research, contribution of original material, editing and approval
of final manuscript; HC, AD, DF, JW and SJ: contribution of original material,
editing and approval of final manuscript; OW, MP, SL and SB: research,
contribution of original material, editing and approval of final manuscript.
Funding This work is supported by a grant from the Chief Scientist’s Office
Scotland (CZH/4/688). AH is funded by an MRC Clinician Scientist Fellowship
(G0802808). The funders and study sponsor will have no role in the study
design; collection, management, analysis and interpretation of data; writing of
the report; and the decision to submit the report for publication.
Competing interests AH, HC, SJ, JW, SL, OW, MP and SB are all
co-investigators on the grant from the Chief Scientist’s Office Scotland
(CZH/4/688) that has been secured to support this study. AH is funded by an
MRC Clinician Scientist Fellowship (G0802808). HC holds an MRC Centre
Grant (G1002033) and a project grant from Bayer Schering Pharma AG. AH
and HC hold the University of Edinburgh Patent ‘Identification of Ectopic
Pregnancies’ number 0712801.0.
Ethics approval Ethical approval has been obtained from the Scotland A
Research Ethics Committee (LREC 12/SS/0005).
Provenance and peer review Not commissioned; internally peer reviewed.
Data sharing statement No additional data are available.
REFERENCES
1. Latthe P, Latthe M, Say L, et al. WHO systematic review of
prevalence of chronic pelvic pain: a neglected reproductive health
morbidity. BMC Public Health 2006;6:177.
2. Daniels JP, Khan KS. Chronic pelvic pain in women. BMJ 2010;341:
c4834.
3. Cheong Y, Stones WR. Chronic pelvic pain: aetiology and therapy.
Best Pract Res Clin Obstet Gynaecol 2006;20:695e711.
4. Stones RW, Mountfield J. Interventions for treating chronic pelvic pain
in women. Cochrane Database Syst Rev 2000;(4):CD000387.
5. Sator-Katzenschlager SM, Scharbert G, Kress HG, et al. Chronic
pelvic pain treated with gabapentin and amitriptyline: a randomized
controlled pilot study. Wien Klin Wochenschr 2005;117:761.
6. Wiffen PJ, McQuay HJ, Edwards JE, et al. Gabapentin for acute and
chronic pain. Cochrane Database Syst Rev 2005;(3):CD005452.
7. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what,
why and how. BMC Med Res Methodol 2010;10:1.
8. Barbour RS. Focus groups. In: Bourgeault I, Dingwall R, de Vries R
eds. The SAGE Handbook of Qualitative Methods in Health
Research. London, UK: Sage Publications Ltd, 2010:327e52.
9. Melnikow J, Kiefe C. Patient compliance and medical research: issues
in methodology. J Gen Intern Med 1994;9:96e105. http://www.nice.org.
uk/aboutnice/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf
10. National Institute for Health and Clinical Excellence. Guide to the
methods of technology appraisal. NICE 2008. http://www.nice.org.uk/
media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf
11. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Research design
considerations for confirmatory chronic pain clinical trials: IMMPACT
recommendations. Pain 2010;149:177e93.
12. Temple R, Ellenberg SS. Placebo-controlled trials and active-control
trials in the evaluation of new treatments. Part 1: ethical and scientific
issues. Ann Intern Med 2000;133:455e63.
13. Ellenberg SS, Temple R. Placebo-controlled trials and active-control
trials in the evaluation of new treatments. Part 2: practical issues and
specific cases. Ann Intern Med 2000;133:464e70.
14. Sculpher MJ, Claxton K, Drummond M, et al. Whither trial-based
economic evaluation for health care decision making? Health Econ
2006;15:667e87.
15. Boyd KA, Fenwick E, Briggs A. Using an iterative approach to
economic evaluation in drug development process. Drug Dev Res
2010;71:470e7.
16. Kelly AM. The minimum clinically significant difference in visual
analogue scale pain score does not differ with severity of pain. Emerg
Med J 2001;18:205e7.
PAGE fraction trail=6.5
Horne AW, Critchley HOD, Doust A, et al. BMJ Open 2012;2:e001297. doi:10.1136/bmjopen-2012-001297 7
Efficacy of gabapentin for chronic pelvic pain in women: study protocol
